Publication & Citation Trends
Publications
555 total
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Cited by 1,336
OpenAlex
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
Cited by 1,574
OpenAlex
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Cited by 3,183
OpenAlex
Research Topics
Colorectal Cancer Treatments and Studies
(200)
Lung Cancer Treatments and Mutations
(192)
Cancer Immunotherapy and Biomarkers
(117)
Cancer Treatment and Pharmacology
(106)
Lung Cancer Research Studies
(87)
Affiliations
Roche (Switzerland)
Novartis (Switzerland)
Baptist Hospital of Miami
Centre National de la Recherche Scientifique
Renault (France)